A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF-κB Signal Pathway and Reducing Reactive Oxygen Species

Figure 6

DIC reduces intracellular ROS activity. (a) Representative flow cytometry images of RANKL-induced ROS production in the presence or absence of pretreated DIC. An H2DCFDA probe detected intracellular ROS in the form of highly fluorescent DCF. (b) With or without DIC intervention, confocal images were measured using a fluorescent probe emitting a fluorescence signal similar to FITC. (c) Quantitative analyses of fluorescent intensity. All bar charts are presented as the ; ; , relative to the non-DIC treatment group.

(a)

(b)

(c)